HIGHLIGHTS
SUMMARY
Many studies have investigated the effects of CYP2D6 polymorphism on the pharmacokinetics (PK) of CYP2D6 substrates. Shu-feng Zhou examined the clinical significance of CYP2D6 polymorphism and found that hepatotoxicity and peripheral neuropathy occurred more frequently in poor metabolizers (PMs) who used perhexiline. Studies have shown that CYP2D6 polymorphism affects the PPF PK profile. Zhang et_al classified people with CYP2D6 polymorphism into four groups: ultra-rapid metabolizers (UMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabolizers (PMs). The authors conducted a meta-analysis to collect the existing PPF PK studies and provide a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.